CJC-1295 (With DAC)

Growth hormone axis Research compound (not approved for human use)

Long-acting growth hormone releasing hormone analog · also known as CJC-1295 DAC, DAC:GRF, Drug Affinity Complex GRF

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

CJC-1295 with DAC (drug affinity complex) is a modified growth-hormone releasing hormone fragment carrying a chemical group that lets it attach to circulating albumin. That attachment slows clearance, so a single dose keeps GH and IGF-1 elevated for days instead of the brief pulse produced by unmodified GHRH analogs. It was developed for clinical use but remains unapproved, and it is distinct from the shorter-acting 'No DAC' (Mod GRF 1-29) form.

Commonly reported dosing (5 mg vial)

Reconstituted with 2 mL → 2.5 mg/mL.

Also sold in 2 mg vials.

Phase	Dose	Volume	U-100 units
Starting	300 mcg	0.12 mL	12
Standard	500 mcg	0.2 mL	20
Higher Per injection; weekly totals of up to about 2 mg are reported.	1 mg	0.4 mL	40

Frequency: Twice weekly (once weekly also described) · Half-life: ~6-8 days (5.8-8.1 days in a human trial)

Open in calculator

Commonly reported dose escalation

Weeks	Dose	Volume	U-100 units
Weeks 1-2	300 mcg	0.12 mL	12
Weeks 3-4	500 mcg	0.2 mL	20
Weeks 5-6	750 mcg	0.3 mL	30
Week 7+	1 mg	0.4 mL	40

Higher steps may need a larger vial or more than one draw. Escalation schedules vary; dosing decisions belong to a licensed clinician.

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
2 mL of bacteriostatic water is added slowly down the inside wall of the 5 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 2.5 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Sealed vials are commonly stored refrigerated (2-8 °C) and protected from light, or frozen for long-term storage.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and not frozen.

Commonly used within 28 days of mixing.

How it works

The peptide activates the GHRH receptor on pituitary somatotroph cells. Because it is bound to albumin, stimulation is continuous rather than pulsatile, which in a small human study raised baseline (trough) GH and IGF-1 while the normal pulse pattern was largely preserved.

Researched for

In a placebo-controlled trial in healthy adults, single doses raised mean GH roughly 2- to 10-fold for 6 days or more and IGF-1 about 1.5- to 3-fold for 9-11 days.
Repeated doses produced a cumulative effect on IGF-1 that persisted for up to about 4 weeks.
Studied for how continuous GHRH-receptor stimulation changes GH pulsatility and trough levels.

Notes

Reference charts differ by vial: a 2 mg vial figure of about 2 mg once weekly is reported alongside a 5 mg vial schedule that escalates from 300 mcg to 1 mg per dose twice weekly; the dose figures here follow the 5 mg chart.
Human data come from a small number of early-phase studies in healthy adults; long-term safety is not established.
Side effects reported in trials include injection-site reactions and transient flushing; sustained GH exposure may differ from physiological pulses.
Often discussed in combination with ipamorelin; the short-acting no-DAC version is a separate entry.